Devroe Eric 4

What Happened
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, was granted 72,981 restricted stock units (RSUs) on May 18, 2026. The grant is reported at $0.00 per share (RSUs are a contingent right to receive common stock in the future), so there was no cash exchanged at grant. This is a compensation award (not a purchase or sale).

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-20 (appears timely).
• Security and amount: 72,981 RSUs granted, reported at $0.00 per RSU.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Each RSU converts to one share on vesting. 16.67% of the RSUs vest on November 18, 2026; the remainder vests in 10 substantially equal quarterly installments thereafter, subject to continuous service.
• Transaction code: A (award/grant).

Context
RSU grants are common executive compensation and do not involve an immediate cash outlay or sale of stock. Vesting conditions mean the shares will be delivered only if the reporting person remains in service through the vesting dates; they do not by themselves indicate an immediate change in ownership or market action.